// App-Quantinova.ai

4003 : REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Researchers

Presenter

  • Andrew X. Zhu

Principal Investigators

  • Chia-Jui Yen

  • Richard S. Finn

  • Peter R. Galle

  • Josep M. Llovet

  • Eric Assenat

  • Giovanni Brandi

  • Ho Yeong Lim

  • Marc Pracht

  • Kun-Ming Rau

  • Philippe Merle

  • Kenta Motomura

  • Izumi Ohno

  • Bruno Daniele

  • Dongbok Shin

  • Guido Gerken

  • Paolo Abada

  • Yanzhi Hsu

  • Masatoshi Kudo

Medical Centers

  • Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA

  • National Cheng Kung University Hospital, Tainan City, Taiwan

  • University of California, Los Angeles, Los Angeles, CA

  • Universitatsmedizin, Mainz, Germany

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • CHU de Montpellier, Montpellier, France

  • Policlinico S. Orsola Malphigi, Bologna, Italy

  • Centre Eugene-Marquis, Rennes, France

  • Chang Gung Memorial Hospital Kaohsiung Branch, Kaohsiung, Taiwan

  • Hopital de la Croix Rousse, Lyon, France

  • Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • G.Rummo Hospital, Benevento, Italy

  • Universtitatsklinikum Essen AoR, Essen, Germany

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, New York, NY

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

Locations

  • Taiwan

  • Japan

  • Italy

  • Germany

  • United States

  • France

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Alfa-fetoprotein

  • Ramucirumab

  • Sorafenib

Outcome

  • Indeterminate

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved